Stephanie Hoeler – SVP, Experience Strategy at TBWA\WorldHealth – explores how the world of medicine should begin to break the binary and the potential leadership role pharma companies, healthcare advertising agencies, and HCPs can take.
This interactive discussion will touch on a wide range of issues, from how the Covid-19 pandemic has affected women’s health globally, to the current state of sexual and reproductive health and rights, and how changing our approach to data can expose important drivers of poor health in women.
Organon on June 3 celebrated the launch of the global women’s health company with employees and women from around the world, as the Organon executive leadership team rang the opening bell at the New York Stock Exchange (NYSE). Recognizing the need to listen to and act on women’s experiences to address the challenges in women’s health, Organon gathered voices from around the world to create the “Wall of Voices,” a multimedia installation outside of the NYSE.
One year after AbbVie’s $63 billion purchase of Allergan, the company is reportedly lining up the sale of a portfolio of women’s drugs and health care products valued at $5 billion.
IPG Health Germany won the communications account around the new women’s health portfolio of pharmaceutical manufacturer DR. KADE Health Care.
Myovant Sciences’ stock rocketed on news that the company was partnering with Pfizer to develop and commercialize Orgovyx (relugolix) for prostate cancer and women’s health.
With a $425 million upfront payment, Bayer bolstered the company’s women’s healthcare pipeline with the acquisition of U.K.-based KaNDy Therapeutics and an investigational treatment for menopause.
The U.S. Food and Drug Administration approved Evofem Biosciences Inc.’s Phexxi (lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.
Merck is spinning off products from the company’s Women’s Health, Legacy Brands and Biosimilars businesses.
Amag Pharmaceuticals Inc. said the company would divest two of women’s health products, after the drugmaker conducted a strategic review under pressure from hedge fund Caligan Partners.